Centessa Pharmaceuticals plc
NASDAQ:CNTABiotechnology
-$0.07 today
- Market cap
- $6.27B
- Beta
- 1.12
- P/E (TTM)
- -24.4
- EPS (TTM)
- -$1.63
Volume 0.00M
Average 2.63M
CNTA Account Payables
Amounts the company owes suppliers for goods and services received.
Centessa Pharmaceuticals plcNASDAQ: CNTA
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 107.7% from a year ago
Account payables stood at $10.66M at the end of Q1 FY2026, up 107.7% from a year earlier and up 40.6% from the prior quarter. Over 3 fiscal years it compounded at -18.2% a year.
Context
- Account payables amounted to 1.7% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +107.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 7.58M USD
- Year-over-year change
- +6.1%
- 4-year CAGR
- -1.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.58M | +6.1% |
| FY2024 | 2024-12-31 | 7.14M | -39.5% |
| FY2023 | 2023-12-31 | 11.82M | -14.6% |
| FY2022 | 2022-12-31 | 13.84M | +71.6% |
| FY2021 | 2021-12-31 | 8.07M | — |
Account Payables vs competitors
How CNTA compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +107.7% is the highest of 10, against a peer median of -13.3%.
- Account payables amounts to 1.7% of total assets for CNTA, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $136.69M USD | +27.3% | +29.0% | 12.7% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥106.81M CNY | +16.1% | +3.8% | 2.7% |
| Sep 2026 | $72M USD | -29.7% | +36.8% | 4.3% | |
| Mar 2026 | $42M USD | -11.5% | -10.5% | 3.2% | |
| Jun 2026 | $12.15M USD | -13.3% | +15.4% | 1.2% | |
| Mar 2026 | $10.66M USD | +107.7% | -18.2% | 1.7% | |
| Sep 2026 | $9.77M USD | +6.3% | +79.7% | 0.9% | |
| Jun 2026 | $8.09M USD | -27.5% | +34.6% | 1.0% | |
| Jun 2026 | $3.08M USD | -45.8% | +42.9% | 0.2% | |
| Sep 2026 | $1.93M USD | -57.7% | -22.9% | 0.2% | |
| Peer median (excluding CNTA) | — | -13.3% | +29.0% | 1.2% | |
Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 595.08M | 393.64M | 128.03M | 383.22M | 61.3M |
| Short-term Investments | 0 | 0 | 128.52M | 98.96M | 233.28M |
| Net Receivables | 16.81M | 26.72M | 39.15M | 45.3M | 60.34M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 993K | 3.27M | 1.62M | 1.78M | 1.83M |
| Total Current Assets | 628.77M | 437.75M | 315.09M | 536.41M | 367.88M |
| Property, Plant & Equipment (Net) | 162K | 1.17M | 12.95M | 11.76M | 10.85M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 282.55M |
| Tax Assets | 0 | 3.51M | 29.65M | 26.59M | 24.78M |
| Other Non-current Assets | 699K | 1.88M | 2.55M | 2.05M | 1.44M |
| Total Non-current Assets | 861K | 6.56M | 45.15M | 40.39M | 319.62M |
| Total Assets | 629.64M | 444.31M | 360.25M | 576.8M | 687.5M |
| Account Payables | 8.07M | 13.84M | 11.82M | 7.14M | 7.58M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 769K | 1.58M | 112K | 835K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.97M | 7.95M | 839K | 10.18M | 35.35M |
| Total Current Liabilities | 24.64M | 38.34M | 39.39M | 58M | 42.94M |
| Long-term Debt | 75.7M | 69.8M | 75.7M | 108.94M | 7.57M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 37.74M | 0 | 29K | 29K | 110.12M |
| Total Non-current Liabilities | 113.44M | 69.8M | 84.62M | 117.26M | 117.7M |
| Total Liabilities | 138.08M | 108.14M | 124M | 175.25M | 160.63M |
| Common Stock | 252K | 265K | 273K | 359K | 405K |
| Retained Earnings | (385.65M) | (601.86M) | (752.95M) | (988.7M) | (1.19B) |
| Accumulated OCI | 688K | (1.5M) | 1.49M | 4.21M | 2.71M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 491.55M | 336.17M | 236.24M | 401.55M | 526.86M |
| Total Debt | 75.7M | 69.8M | 84.59M | 117.23M | 7.57M |
| Net Debt | (519.38M) | (323.84M) | (43.44M) | (266M) | (53.73M) |
Centessa Pharmaceuticals plc
NASDAQ:CNTA
Intrinsic Alpha fair value
Locked
Current Price
$40.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.